What's new? Log in Free sign up

VistaGen Therapeutics (VTGN) News and press releases

Company Profile

News

From Benzinga Pro

Why VistaGen Therapeutics Shares Are Trading Higher Today

Penny Stocks, Movers

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Vistagen Announces Data From Phase 3 Open-Label Study To Evaluate Safety And Tolerability Of PH94B; Was Safe And Well Tolerated

Biotech, General

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders,

Vistagen Announces Completion Of Last Patient, Last Visit In Phase 1 Clinical Trial Of Itruvone, An Investigational Pherine Nasal Spray For Major Depressive Disorder; Top Line Results Anticipated In Q2 2023

Biotech, News, FDA, General

U.S. Phase 1 study with newly optimized formulation intended to facilitate Phase 2B development of itruvone as a stand-alone treatment of major depressive disorder Top line results anticipated

Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.

Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice's Federal Bureau of Investigation.

12 Health Care Stocks Moving In Friday's Intraday Session

Why Alteryx Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

VistaGen Therapeutics's Return On Capital Employed Insights

12 Health Care Stocks Moving In Thursday's Pre-Market Session

VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial

Biotech, Earnings, News, Penny Stocks, Health Care, General

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement.

VistaGen Therapeutics Q3 EPS $(0.05) Beats $(0.07) Estimate, Sales $179.60K Beat $150.00K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year. The company

Earnings Scheduled For February 7, 2023

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.

Preview: VistaGen Therapeutics's Earnings

Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Vistagen Announces First Participants Dosed In Phase 1 Clinical Trial Of PH10, An Investigational Pherine Nasal Spray For Major Depressive Disorder

Biotech, News, FDA, General

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major

Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In Q1 2023

Biotech, News, FDA, General

In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ:VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive

Press releases

From Benzinga Pro

Thinking about buying stock in Vistagen Therapeutics, NVIDIA, SoFi Technologies, Carnival Corp, or Nike?

Opinion, Press Releases

NEW YORK, March 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTGN, NVDA, SOFI, CCL, and NKE.

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

Long-term intranasal administration of fasedienol, used as-needed up to four times a day in daily life, was safe and well-tolerated in nearly 500 patients with social anxiety disorder (SAD) Patients self-administered

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

U.S. Phase 1 study with newly optimized formulation intended to facilitate Phase 2B development of itruvone as a stand-alone treatment of major depressive disorder Top line results anticipated in Q2 2023 Vistagen

Vistagen to Present at Cowen 43rd Annual Health Care Conference

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

PH80 patent portfolio now includes U.S. patents for treatment of both hot flashes and migraine Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for

Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results

Pherin acquisition completed; all future royalty payment obligations related to PH94B and PH10 eliminated, three new drug candidates added to Vistagen's pipeline PH94B Phase 3 program for social anxiety disorder

Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023

Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today

Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipeline Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the

NASDAQ Stocks Gaining Momentum Below $1: VVPR, FFIE, VTGN, IDEX

Naples, FL--News Direct--Investing in stocks priced under $1 on the NASDAQ has the potential to be a profitable venture for investors. The market attracts a lot of attention from investors because it has the potential

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major

Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023

San Francisco, California--News Direct--By Rachael Green, BenzingaIn the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ:VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

Topline results of the exploratory Phase 2 clinical study anticipated in Q1 2023 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals

Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder

Vistagen's recent patent filings in the U.S. and numerous additional countries mark the next step in the Company's ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.